6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of April 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Change of Director’s Interest Notice x 3 |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: April 29, 2025
2
Exhibit 99.1
Appendix 3Y
Change of Director’sInterest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now mustbe given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Alterity Therapeutics Limited |
|---|---|
| ABN | 37 080 699 065 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | Peter Marks |
|---|---|
| Date of last notice | 07 April 2025 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trustmade available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | (1) <br> Indirect - Lampam Pty Ltd<br><br> <br>(2) <br> Direct<br><br> <br>(3) <br> Indirect - Shanti Capital Pty Ltd <Peter Marks Super Fund A/C> |
|---|---|
| Nature of indirect interest (including registered holder) | (1) <br> Director<br><br> <br>(2) <br> N/A<br><br> <br>(3) <br> SMSF |
| Date of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(2.1) N/A<br><br> <br>(2.2) N/A<br><br> <br>(3.1) N/A<br><br> <br>(3.2) 24 April 2025 |
| No. of securities held prior to change | (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES<br><br> <br>(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br><br> <br>(2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @<br> $0.01<br><br> <br>(3.1) 1,818,182 - FULLY PAID ORDINARY SHARES<br><br> <br>(3.2) NIL - LISTED OPT EXP 26/02/2027 @ $0.028 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director’sInterest Notice
| Class | (1.1) FULLY PAID ORDINARY SHARES<br><br> <br>(1.2) LISTED OPT EXP<br> 31/08/2026 @ $0.01<br><br> <br>(2.1) UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(2.2) UNLISTED<br> OPT EXP 30/12/2027 @ $0.01<br><br> <br>(3.1) FULLY PAID ORDINARY SHARES<br><br> <br>(3.2) LISTED OPT EXP 26/02/2027 @ $0.028 |
|---|---|
| Number acquired | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(2.1) NIL<br><br> <br>(2.2) NIL<br><br> <br>(3.1) NIL<br><br> <br>(3.2) 606,061 - LISTED OPT EXP 26/02/2027 @ $0.028 |
| Number disposed | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(2.1) NIL<br><br> <br>(2.2) NIL<br><br> <br>(3.1) NIL<br><br> <br>(3.2) NIL |
| Value/Consideration | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(2.1) N/A<br><br> <br>(2.2) N/A<br><br> <br>(3.1) N/A<br><br> <br>(3.2) NIL CONSIDERATION |
| No. of securities held after change | (1.1) 7,185,968 - FULLY PAID ORDINARY SHARES<br><br> <br>(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br><br> <br>(2.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(2.2) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @<br> $0.01<br><br> <br>(3.1) 1,818,182 - FULLY PAID ORDINARY SHARES<br><br> <br>(3.2) 606,061 - LISTED OPT EXP 26/02/2027 @ $0.028 |
| Nature of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(2.1) N/A<br><br> <br>(2.2) N/A<br><br> <br>(3.1) N/A<br><br> <br>(3.2) Options Issue |
Part 2 - Change of director’s relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder<br><br> <br>(if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration | N/A |
| Interest after change | N/A |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
Part 3 - +Closed period
| Were the interests in the securities or c+ontracts detailedabove traded during a closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3
Appendix 3Y
Change of Director’sInterest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASXas soon as available. Information and documents given to ASX becomes ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Alterity Therapeutics Limited |
|---|---|
| ABN | 37 080 699 065 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | Lawrence Gozlan |
|---|---|
| Date of last notice | 07 April 2025 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust madeavailable by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | (1) Indirect - Montoya Pty Ltd <Buttercup A/C> |
|---|---|
| Nature of indirect interest (including registered holder) | (1) Director |
| Date of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) N/A<br><br> <br>(1.4) 24 April 2025 |
| No. of securities held prior to change | (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01<br><br> <br>(1.3) 4,545,455 - FULLY PAID ORDINARY SHARES<br><br> <br>(1.4) NIL - LISTED OPT EXP 26/02/2027 @ $0.028 |
| Class | (1.1) UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.2) UNLISTED OPT EXP 30/12/2027<br> @ $0.01<br><br> <br>(1.3) FULLY PAID ORDINARY SHARES<br><br> <br>(1.4) LISTED OPT EXP 26/02/2027 @ $0.028 |
| Number acquired | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(1.3) NIL<br><br> <br>(1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 4
Appendix 3Y
Change of Director’sInterest Notice
| Number disposed | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(1.3) NIL<br><br> <br>(1.4) NIL |
|---|---|
| Value/Consideration | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) N/A<br><br><br><br>(1.4) NIL CONSIDERATION |
| No. of securities held after change | (1.1) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.2) 50,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01<br><br> <br>(1.3) 4,545,455 - FULLY PAID ORDINARY SHARES<br><br> <br>(1.4) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 |
| Nature of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) N/A<br><br> <br>(1.4) Options Issue |
Part 2 - Change of director’s relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration | N/A |
| Interest after change | N/A |
Part 3 - +Closed period
| Were the interests in the securities or c+ontracts detailedabove traded during a closed period where prior written clearance was required? | No. |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 5
Appendix 3Y
Change of Director’sInterest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASXas soon as available. Information and documents given to ASX becomes ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Alterity Therapeutics Limited |
|---|---|
| ABN | 37 080 699 065 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | Brian Meltzer |
|---|---|
| Date of last notice | 07 April 2025 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust madeavailable by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | (1) Direct<br><br> <br>(2) Indirect - BT PORTFOLIO SERVICES |
|---|---|
| Nature of indirect interest (including registered holder) | (1) N/A<br><br> <br>(2) SMSF |
| Date of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) 24 April 2025<br><br> <br>(1.4) N/A<br><br> <br>(1.5) N/A<br><br> <br>(2) N/A |
| No. of securities held prior to change | (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES<br><br> <br>1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br><br> <br>(1.3) NIL - LISTED OPT EXP 26/02/2027 @ $0.028<br><br> <br>(1.4) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.5) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01<br><br> <br>(2) 326,666 - FULLY PAID ORDINARY SHARES |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 6
Appendix 3Y
Change of Director’sInterest Notice
| Class | (1.1) FULLY PAID ORDINARY SHARES<br><br> <br>(1.2) LISTED OPT EXP 31/08/2026 @<br> $0.01<br><br> <br>(1.3) LISTED OPT EXP 26/02/2027 @ $0.028<br><br> <br>(1.4) UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.5) UNLISTED OPT EXP 30/12/2027 @ $0.01<br><br> <br>(2) FULLY PAID ORDINARY SHARES |
|---|---|
| Number acquired | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028<br><br> <br>(1.4) NIL<br><br> <br>(1.5) NIL<br><br> <br>(2) NIL |
| Number disposed | (1.1) NIL<br><br> <br>(1.2) NIL<br><br> <br>(1.3) NIL<br><br> <br>(1.4) NIL<br><br> <br>(1.5) NIL<br><br> <br>(2) NIL |
| Value/Consideration | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) NIL CONSIDERATION<br><br> <br>(1.4) N/A<br><br> <br>(1.5) N/A<br><br> <br>(2) N/A |
| No. of securities held after change | (1.1) 9,415,584 - FULLY PAID ORDINARY SHARES<br><br> <br>(1.2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br><br> <br>(1.3) 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028<br><br> <br>(1.4) 7,000,000 - UNLISTED OPT EXP 17/09/2025 @ $0.09<br><br> <br>(1.5) 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01<br><br> <br><br><br> <br>(2) 326,666 - FULLY PAID ORDINARY SHARES |
| Nature of change | (1.1) N/A<br><br> <br>(1.2) N/A<br><br> <br>(1.3) Options Issue<br><br> <br>(1.4) N/A<br><br> <br>(1.5) N/A<br><br> <br>(2) N/A |
Part 2 - Change of director’s relevant interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 7
Appendix 3Y
Change of Director’sInterest Notice
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration | N/A |
| Interest after change | N/A |
Part 3 - +Closed period
| Were the interests in the securities or c+ontracts detailedabove traded during a closed period where prior written clearance was required? | No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 8